相关实验视频
Updated: May 20, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
244
阿普塔默功能化脂质体与表胺-4和辅酶Q10共同装载 通过改善胰腺β细胞功能来改善2型糖尿病
Shangying Xiao1, Lei Rao2, Canying Yan1
1Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Dongguan, People's Republic of China.
International journal of nanomedicine
|March 24, 2025
概括
一种新的脂质体联合递送系统有效地准胰腺β细胞,改善其功能并缓解2型糖尿病. 这个系统增强了抗氧化能力,并恢复了糖尿病模型中的细胞结构.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 内分泌学 在内分泌学.
背景情况:
- 氧化应激会损害胰腺β细胞的功能,导致2型糖尿病 (T2DM).
- 埃克萨纳提德-4 (Ext-4) 改善了血糖控制,但没有恢复β细胞功能.
- 辅酶Q10 (CoQ10) 具有抗氧化特性,但其生物利用性较差,限制了其治疗用途.
研究的目的:
- 开发一种针对胰腺的脂质体共递系统 ((E+Q) -Lip-Apt) 封装Ext-4和CoQ10.
- 评估 (E+Q) -Lip-Apt在保护胰腺β细胞和治疗T2DM方面的疗效.
主要方法:
- 使用薄膜分散和通过实验设计优化 (E+Q) -Lip-Apt的配方.
- 在体外评估MIN6细胞中抗氧化能力,线粒体膜潜力和氧化应激标志物.
- 在糖尿病小鼠体内评估,包括葡萄糖耐受性,胰岛素敏感性,脂质代谢和组织学分析.
主要成果:
- (E+Q) -Lip-Apt显示了高封装效率和稳定性.
- 与Ext-4相比,体外研究显示出更优异的活性氧物种 (ROS) 清除和线粒体功能保护.
- 在体内研究显示,葡萄糖平衡,胰岛素敏感性,肝脂代谢和抗氧化酶活性显著改善,同时还恢复了胰腺β细胞结构.
结论:
- 开发的 (E+Q) -Lip-Apt系统有效地准胰腺β细胞.
- (E+Q) -Lip-Apt可以缓解氧化压力,恢复胰腺β细胞功能,缓解糖尿病.
- 这种有针对性的输送系统为T2DM提供了一个有前途的治疗策略.
相关概念视频
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
Insulin: Biosynthesis, Chemistry, and Preparation
326
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
326
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144

